The subgroup analysis of T2DM and exacerbated COPD revealed that metformin users receiving >2 OAD treatments had lower risk of all-cause mortality, but insulin therapy didn’t have such benefit. This evidence concerns the gene INS and type 2 diabetes mellitus.